Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: A randomized, phase III study by the Danish breast cancer cooperative group Full Text
Journal of Clinical Oncology,  Clinical Article

Nielsen DL et al. – GD compared with docetaxel demonstrated increased TTP in metastatic breast cancer. RR and OS were similar. The addition of gemcitabine failed to demonstrate any clinically meaningful benefit when combined with docetaxel.

Methods

  • Predominantly human epidermal growth factor receptor 2 (HER2) –negative patients were randomly assigned to gemcitabine (1,000 mg/m2) on days 1 and 8 plus docetaxel (75 mg/m2) on day 8 or to docetaxel (100 mg/m2) on day 1, every 21 days
  • Patients were untreated or had prior (neo)adjuvant chemotherapy or a single anthracycline-based chemotherapy regimen for metastatic breast cancer
  • Primary end point was time to progression (TTP), and secondary end points were OS, response rate (RR), and toxicity

Results
  • 170 patients were allocated to GD, and 167 were allocated to docetaxel
  • Median TTP on GD was 10.3 months versus 8.3 months on docetaxel (HR, 0.77; 95% CI, 0.59 to 1.01; log-rank P = .06)
  • Adjusted Cox proportional model for TTP showed significant difference favoring combination (HR, 0.68; 95% CI, 0.51 to 0.90; P = .007)
  • RR was similar (GD, 36%; docetaxel, 34%), and OS was not different (P = .57)
  • Grades 3 to 4 neutropenia was common (GD, 75%; docetaxel, 69%); infection was reported in 26% and 21% of patients in the GD and docetaxel groups, respectively
  • Grades 3 to 4 thrombocytopenia was more frequent with GD (GD, 16%; docetaxel, 0.6%), and peripheral neuropathy was higher with docetaxel (GD, 5%; docetaxel, 16%)

Please login or register to follow this author.
► Click here to access Full Text, PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

    Currently, there are no available articles.

Your Unread Messages in Oncology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

<

Most Popular Oncology Articles

Indexed Journals in Oncology: Journal of Clinical Oncology, Cancer Research, Annals Oncologymore

Make smarter career moves with less time.

Sign up for our free job placement service today and have a dedicated career consultant help locate the right physician job for you!
Click Here for more information.

Get Started Now!

Free-of-charge, no obligation.

Terms and Conditions For M3 Career Consult

By registering with the M3 Career Consult service you authorize M3 USA Corporation to represent you in your job search. The following is a summary of the terms of our service and our mutual obligations to help you find a job:

  • You designate M3 to act as your agent and represent you in your job search;
  • You will not pay us for this service
  • You will advise us of any companies or positions to which you apply or have applied;
  • You will advise us if you believe you are not capable of performing a position for which we submit you, or for which you interview;
  • You will keep all information we provide you about companies or positions strictly confidential;
  • You will promptly provide us with information we request of you;
  • You will make yourself reasonably available for phone, video and in-person conversations and interviews;
  • You will be truthful in all of your communications with us; and
  • You will advise us if anything above changes.
 

The Top Read Articles of 2014 are Now Available

Scouring thousands of peer-reviewed journals and popular press, Our Editors just released the Top Read Articles of the Year. See the Top Read List